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Abstract
Background: The effects of systolic blood pressure (SBP), serum total cholesterol (TC), fasting plasma glucose (FPG), and
body mass index (BMI) on the risk of cardiovascular diseases (CVD) have been established in epidemiological studies, but
consistent estimates of effect sizes by age and sex are not available.
Methods: We reviewed large cohort pooling projects, evaluating effects of baseline or usual exposure to metabolic risks on
ischemic heart disease (IHD), hypertensive heart disease (HHD), stroke, diabetes, and, as relevant selected other CVDs, after
adjusting for important confounders. We pooled all data to estimate relative risks (RRs) for each risk factor and examined
effect modification by age or other factors, using random effects models.
Results: Across all risk factors, an average of 123 cohorts provided data on 1.4 million individuals and 52,000 CVD events.
Each metabolic risk factor was robustly related to CVD. At the baseline age of 55–64 years, the RR for 10 mmHg higher SBP
was largest for HHD (2.16; 95% CI 2.09–2.24), followed by effects on both stroke subtypes (1.66; 1.39–1.98 for hemorrhagic
stroke and 1.63; 1.57–1.69 for ischemic stroke). In the same age group, RRs for 1 mmol/L higher TC were 1.44 (1.29–1.61) for
IHD and 1.20 (1.15–1.25) for ischemic stroke. The RRs for 5 kg/m
2 higher BMI for ages 55–64 ranged from 2.32 (2.04–2.63) for
diabetes, to 1.44 (1.40–1.48) for IHD. For 1 mmol/L higher FPG, RRs in this age group were 1.18 (1.08–1.29) for IHD and 1.14
(1.01–1.29) for total stroke. For all risk factors, proportional effects declined with age, were generally consistent by sex, and
differed by region in only a few age groups for certain risk factor-disease pairs.
Conclusion: Our results provide robust, comparable and precise estimates of the effects of major metabolic risk factors on
CVD and diabetes by age group.
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Introduction
Globally, roughly 17 million deaths are caused by cardiovas-
cular disease (CVD) and diabetes each year [1]. Although the
major metabolic risk factors for these diseases have been
characterized in epidemiological studies, consistent measurements
of their effects by age, sex and region are not available.
Understanding the effects of metabolic risk factors on CVD
mortality and burden of disease are important inputs for policy
and priority setting related to disease prevention.
Population-based risk assessment requires data on population
exposure to risk factors and on the magnitude of their effects on
different disease outcomes [2,3]. Effect estimates in prior global
comparative risk assessment (CRA) analyses of metabolic risk
factors including systolic blood pressure (SBP), serum total
cholesterol (TC), fasting plasma glucose (FPG), and body mass
index (BMI) were based on the Asia Pacific Cohort Studies
Collaboration (APCSC) and selected other cohort pooling studies
[3–13]. Since that time, several additional meta-analyses have
become available for Western and Asian populations [14–22].
There is, however, no systematic evaluation and comparison of
these sources for new global and national risk assessments,
including potential heterogeneity by age, sex, or region. The aim
of this study was to provide robust, comparable, and consistent
effects of major metabolic risk factors on CVD and diabetes,
including variation in these effects by age, sex, or region.
Methods
Metabolic risk factors
We compared and pooled RRs for the effects of key metabolic
risk factors: SBP, TC, FPG, and adiposity measured by BMI, from
major global pooling projects. For SBP, TC, and FPG, we focused
on the usual distribution, i.e., the distribution that has been
corrected for temporal changes in measurement over time (such
data were not available for BMI; see also below). The choice of
exposure metrics was based on their associations with disease
outcomes and on the availability of worldwide exposure data in
previously described systematic analyses [23–26]. In particular, we
do not present results for other related risk factors such as low-
density lipoprotein (LDL) cholesterol, Hemoglobin A1c, waist
circumference, and waist-to-hip ratio, because global exposure
data to subsequently quantify effects on disease burdens are
significantly more limited [24–26].
Data sources
To obtain RR per unit of exposure for diseases with probable or
convincing etiologic associations with each risk factor, we used
existing meta-analyses of epidemiological studies. We selected
large comprehensive pooling projects of observational studies that
estimated the effects of baseline or usual exposure for the risk
factors and outcomes of interest by age group. Even when
randomized studies were available, we used observational studies
because (i) they estimate the effect of risk factor levels on disease
outcome as opposed to the effect of a particular pharmacological
intervention which may act through risk factor reduction as well as
other pathways, (ii) they estimate the long-term effects (over years
or decades) of exposure to risk factors as opposed to effect of short-
term changes due to treatment in randomized trials, and (iii) they
generally have larger sample sizes and can provide more precise
RRs for more detailed age groups and disease categories.
Randomized trials were used to support the evidence on the
presence of causal effects from observational studies.
The sources used were the Asia Pacific Cohort Studies
Collaboration (APCSC), the Diabetes Epidemiology: Collabora-
tive analysis of Diagnostic criteria in Europe (DECODE), the
Emerging Risk Factor Collaboration (ERFC) and the Prospective
Studies Collaboration (PSC) [9–13,16–22,27–29]. All four cohort
pooling studies have large numbers of participants and events that
allow the estimation of RRs by age and disease outcome. Further,
all these pooling studies used individual level data which allows for
more consistent adjustment for confounders. PSC included only
fatal events, while APCSC and ERFC included both fatal and
non-fatal events. ERFC and PSC excluded participants with pre-
existing vascular disease, while APCSC did not. Some cohorts
were included in both multiple pooling studies but the overlaps
were relatively small. We therefore used results from all of the
above-mentioned pooling projects when available. All pooling
studies included in this analysis adjusted for age and sex, and
accounted for differences in risk by cohort. We did not use the
National Cancer Institute (NCI) Cohort Consortium [14] and a
recent pooled analysis of Asian cohorts [15] for BMI effect sizes
because these studies reported RRs for cardiovascular diseases
(CVD) combined but not separately for ischemic heart disease
(IHD) and stroke. Most data are from published sources but, when
possible, re-analyses were done to obtain RRs for diseases and age
groups of interest.
When possible, we used RRs for SBP, TC and FPG that were
adjusted for regression dilution bias using repeated exposure
measurements. Evidence from a large prospective study with
multiple measurements of weight and height showed that
regression dilution bias did not substantially affect the RRs for
BMI, reflecting its relative stability compared with the other
metabolic risk factors [30]. In their published results, the pooling
studies used different methods for correcting regression dilution
bias: e.g., PSC used age-specific correction factors and also
accounted for time between baseline risk factor measurements and
the occurrence of events. We conducted a re-analysis of APCSC
for SBP to use consistent approaches with the PSC meta-analysis.
DECODE and ERFC did not adjust for regression dilution bias.
Disease outcomes
The disease outcomes included in this analysis were: ischemic
heart disease (IHD) (ICD-10 codes I20–I25), ischemic stroke (I63,
I65–I67, I69.3), hemorrhagic stroke (I60-62, I69.0-2), hypertensive
heart disease (HHD) (I11–I13), aortic aneurysm (I71), rheumatic
heart disease (RHD) (I01, I02.0, I05–I09), inflammatory heart
disease (I33, I42), and diabetes (E10–E14). Cardiovascular
outcomes reported in the pooling projects other than those
reported above were included in the category ‘‘Other cardiovas-
Cardiometabolic Risk Effect Sizes
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within each cohort.
Table 1 presents the selected risk factors and the disease
outcomes affected by each risk factor using evidence from
observational studies, supported by randomized trials when
available and applicable [31–33]. Specifically, randomized trials
have shown that reducing blood pressure lowers the risk of
mortality from heart failure [32,33], which is considered an
intermediate, vs. underlying, cause of death [34]. Therefore, we
included cardiovascular diseases that lead to heart failure such as
rheumatic heart disease as outcomes for SBP, but the reported
RRs should only be applied to mortality from these causes (as
opposed to incidence) because the incidence of diseases like RHD
and other inflammatory heart diseases is unlikely to be affected by
SBP.
Table 1. Outcomes associated with each risk factor, studies from which RRs were extracted, and procedures for estimating RRs by
age group.
Disease outcome Studies that reported RRs Procedures for estimating RRs in standardized age groups
Systolic blood pressure (SBP)
Ischemic heart disease (IHD) PSC Interpolation and extrapolation
APCSC Interpolation and extrapolation
Ischaemic stroke PSC Interpolation and extrapolation
APCSC Interpolation and extrapolation
Haemorrhagic stroke PSC Interpolation and extrapolation
APCSC Interpolation and extrapolation
Hypertensive heart disease PSC Redistribution from a single age group using PSC ‘‘SBP-other vascular diseases’’ age pattern
APCSC Interpolation and extrapolation
Rheumatic heart disease
a PSC Redistribution from a single age group using PSC SBP-‘‘other vascular diseases’’ age pattern
Inflammatory heart disease
a PSC Redistribution from a single age group using PSC ‘‘SBP-other vascular diseases’’ age pattern
Aortic aneurysm PSC Redistribution from a single age group using PSC ‘‘SBP-other vascular diseases’’ age pattern
All other cardiovascular diseases
b PSC Redistribution from a single age group using PSC ‘‘SBP-other vascular diseases’’ age pattern
APCSC Redistribution from a single age group using PSC ‘‘SBP-other vascular diseases’’ age pattern
Total cholesterol (TC)
IHD PSC
c Interpolation and extrapolation
APCSC Data provided in GBD age groups
Ischemic stroke PSC Interpolation and extrapolation
APCSC Data provided in GBD age groups
Fasting plasma glucose (FPG)
IHD DECODE Interpolation and extrapolation
APCSC Interpolation and extrapolation
ERFC Interpolation and extrapolation.
Total stroke DECODE Interpolation and extrapolation
APCSC Interpolation and extrapolation
ERFC Interpolation and extrapolation
Body mass index (BMI)
IHD PSC Interpolation and extrapolation
APCSC Interpolation and extrapolation
ERFC Interpolation and extrapolation
Ischaemic stroke PSC Redistribution from a single age group using PSC BMI-total stroke age pattern
APCSC Interpolation and extrapolation
ERFC Interpolation and extrapolation
Haemorrhagic stroke PSC Redistribution from a single age group using PSC BMI-total stroke age pattern
ERFC Interpolation and extrapolation
Diabetes PSC Interpolation and extrapolation
APCSC Interpolation and extrapolation
aRRs apply to mortality but not to incidence and is included because of the benefits of lower blood pressure for reduced heart failure mortality.
bThis residual category contains a number of ICD codes. The proportion of deaths from the constituent diseases is likely to vary across world regions and even across
cohorts in the same meta-analysis.
cA quadratic age model was used instead of a log-linear age model as this fit the data better.
doi:10.1371/journal.pone.0065174.t001
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We used RRs for both sexes combined because results of the
included meta-analyses had shown that RRs between men and
women were similar [10–13,20–22]. Based on prior evidence that
proportional effects of some metabolic risk factors vary by age, a
key aim was to establish quantitative estimates of interaction by
age. We estimated RRs for the following age groups: 25–34, 35–
44, 45–54, 55–64, 65–74, 75–84 and 85+ years. We used the
following approach to obtain RRs by the selected age groups from
different sources (Table 1):
N When RRs were provided by age groups that differed from the
above groups, we used interpolation to obtain RRs by the
selected age groups.
N When RRs were provided for a narrower age range, we used
extrapolation to estimate RRs for younger and/or older age
groups.
N When RRs were provided for all ages combined, we re-
analysed original data when these were accessible to the
authors. If re-analysis was not possible, we assigned the single
RR to the median age at event and used the age-association of
the most similar risk factor-disease pair to estimate RRs by the
selected age groups (redistribution).
Our interpolation and extrapolations used a linear relationship
between ln(RR) and midpoint of age in each age category. This
model had the best fit among a range of models including linear,
quadratic, and cubic relationships between age and RR or ln(RR).
The procedures used for different risk factor-disease pairs are
reported in Table 1.
Uncertainty of RRs
The uncertainty of the estimates of RRs has two components:
(1) the (sampling) uncertainty of the RRs in the original source and
(2) the uncertainty associated with conversion to age-specific RRs
as outlined above. To estimate the overall uncertainty, we used a
statistical simulation approach: in each of the 1,000 iterations, we
drew a ln(RR) for each age group in the published meta-analyses
from a normal distribution characterized by the reported ln(RR)
and its standard error. We fitted a linear model to this set of age-
specific ln(RR)s, and used the fitted model to estimate an RR for
each selected age group. The distributions of the 1,000 estimated
ln(RR)s were used to obtain the standard errors of the ln(RR)s in
the selected age groups. We then pooled the age-specific RRs from
multiple sources using a random effects model (meta.summaries
command in the open-source statistical software R version 2.11.1).
Theoretical minimum-risk exposure distribution (TMRED)
An additional input required for risk assessment is an alternative
exposure distribution relative to which the effects of risk factors are
measured. The theoretical minimum-risk exposure distribution
(TMRED) is an alternative exposure distribution that aims to
measure the effects of all non-optimal levels of exposure in a
comparable way across risk factors [2,3,35,36]. TMRED is the
distribution that corresponds to the lowest risk of all-cause
mortality. Since all metabolic indicators are necessary to sustain
life, their ‘exposure-response’ relationship is J-shaped or U-shaped,
i.e. there could be increased risk of adverse outcomes below some
levels [18,22]. However, the subjects in epidemiological studies
often have exposures that do not allow reliable estimation of
optimally low levels, i.e. where benefits stop and harms begin. For
example, many Western cohorts include fewer subjects with low
BMI levels; similarly, SBP levels at which the dose-response
relationship with CVD may flatten or reverse seem to be below
those seen in most epidemiological studies. As a result, to select
TMREDs for the risk factors of interest, we used both the evidence
from epidemiological studies with the levels of exposure observed
in populations that are considered low-risk, e.g. populations that
consume low salt for blood pressure and those that consume low
animal fat diets for serum cholesterol [5,6]. Specifically, we
selected TMREDs as the lowest levels observed in observational,
and when relevant randomised, epidemiological studies as long as
the selected level was also seen at the population level regardless of
age or sex. We used the same TMRED for both sexes and all age
groups because the associations of metabolic risk factors with age
are relatively flat in low-exposure populations [37,38].
In addition to an empirically-based mean, the TMRED may
also have a standard deviation (SD), on the premise that even in
the absence of major environmental risk factors, there is some
residual variation in metabolic risk factors in the population.
Empirically, the SD of metabolic risk factors tends to be smaller in
populations that have a lower mean, with an approximately linear
relationship [6]. We used this relationship to estimate the SD of
TMRED once its mean was established.
Results
Across all risk factors, an average of 123 cohorts provided data
on 1.42 million individuals having 52,000 CVD events. A total of
99 cohorts with 1.38 million participants and 65,000 CVD events
informed the RRs for SBP. For TC, 1.2 million participants
having 59,000 CVD events from 92 cohorts provided data for this
analysis. BMI was the risk factor with effect estimates based on the
largest number amount of data: 163 cohorts with 2.43 million
participants and 70,000 CVD events. Of the four metabolic risk
factors, FPG RRs were based on the fewest events, 7,000 events
among 372,000 participants in 116 cohorts.
Figure 1 presents the forest plot for the estimated effects of SBP
on CVD outcomes. When age-specific RRs were available, we
observed a clear age gradient, with smaller RRs in older ages. At a
baseline age group of 55–64, the RR for SBP was largest for
hypertensive heart disease, showing a more than doubling of the
risk of this disease for each 10 mmHg higher SBP (2.16; 95% CI
2.09–2.24); this was followed by the effects on both stroke subtypes
which had a two thirds increase in risk (1.66; 1.39–1.98 for
haemorrhagic stroke and 1.63; 1.57–1.69 for ischemic stroke); it
was smallest for rheumatic heart disease (1.17; 1.11–1.23).
The results from pooling two meta-analyses that reported RRs
for TC are presented in Figure 2. The RRs were consistent across
PSC and APCSC, except for the estimated effect of TC on IHD in
those younger than 55 years of age, which was larger in PSC.
There was a reduction in the RRs of IHD and ischaemic stroke
with increasing age, similar to that seen for SBP. Indeed, the 95%
confidence interval of the pooled RR included the null effect for
ischaemic stroke in ages 75 years and older. There is evidence,
from randomized trials of statins, that lowering serum cholesterol
in participants with high CVD risk may lower the risk of stroke in
those aged 70 years and older [39,40]. However, this effect may be
mediated through pathways other than lipid lowering, e.g.,
atheromatous plaque stabilization anti-inflammatory effects, or
inhibition of platelet aggregation [41].
Figure 3 summarizes the RR estimates for the associations of
BMI with CVD and diabetes. RRs for the estimated effect of BMI
on diabetes and hypertensive heart disease were larger in Western
cohorts as compared with Asian cohorts in adults ,55 years old,
perhaps due to longer exposure to high BMI in Western
populations. Because there was no association between BMI and
haemorrhagic stroke for BMIs up to 25 kg/m
2 in APCSC, ERFC
Cardiometabolic Risk Effect Sizes
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2
pooled from these two meta-analyses.
Figure 4 presents the forest plots for RRs per unit of FPG from 3
pooling studies. APCSC and ERFC did not report effects for
subtypes of stroke separately, so we used RRs for stroke subtypes
combined. Like the other metabolic risks, RRs declined with
increasing age. The association between FPG and stroke was not
statistically significant up to 55 years of age, due to non-significant
protective effects in the DECODE study.
Theoretical minimum-risk exposure distributions
(TMREDs)
In previous CRA analyses, the mean(SD) of the TMREDs for
metabolic risks were as follows: SBP 115(6) mmHg; TC 3.8(0.6)
mmol/L; BMI 21(1) kg/m
2; and FPG 4.9(0.3) mmol/L. More
recent evidence from randomized trials of antihypertensive drugs
suggests that benefits of lowering blood pressure may continue to
110 mmHg or lower [32]; the lowest observed levels in the
Figure 1. Relative risks (RRs) for diseases associated with systolic blood pressure (SBP). The figure shows RRs for 10 mmHg higher usual
SBP. The figure shows RRs converted to comparable age group as described in Methods. See Table S1 for RRs in original age groups from each study.
RRs for rheumatic heart disease and inflammatory heart disease apply only to deaths and those for other outcomes to deaths and incidence. The
percentage of variation in the pooled estimates that is due to statistical heterogeneity was evaluated using the I
2 statistic for each age group and
outcome. Of all outcomes and age groups analyzed, only two age groups in the pooled analysis for hemorrhagic stroke had non-zero I
2 values:
I
2=44.4% for ages 35–44 years, and I
2=24.3% for ages 55–64 years.
doi:10.1371/journal.pone.0065174.g001
Cardiometabolic Risk Effect Sizes
PLOS ONE | www.plosone.org 5 July 2013 | Volume 8 | Issue 7 | e65174Figure 2. Relative risks (RRs) for diseases associated with serum total cholesterol (TC). The figure shows RRs for 1 mmol/L higher usual TC.
The figure shows RRs converted to comparable age group as described in Methods. See Table S1 for RRs in original age groups from each study. The
percentage of variation in the pooled estimates that is due to statistical heterogeneity was evaluated using the I
2 statistic for each age group and
outcome. Of all the outcomes and age groups analyzed, only ages 35–44 years in the pooled analysis for IHD had a non-zero I
2 value of 58.8%.
doi:10.1371/journal.pone.0065174.g002
Figure 3. Relative risks (RRs) for diseases associated with body mass index (BMI). The figure shows RRs for 5 kg/m
2 higher baseline BMI.
The figure shows RRs converted to comparable age group as described in Methods. See Table S1 for RRs in original age groups from each study. The
percentage of variation in the pooled estimates that is due to statistical heterogeneity was evaluated using the I
2 statistic for each age group and
outcome. Of all the outcomes and age groups analyzed, the three age groups below age 65 years in the pooled analysis for hypertensive heart
disease had non-zero I
2 values: 79.2% for ages 35–44 years, 69.0% for ages 45–54 years, and 37.2% for ages 55–64 years. *The associations with
haemorrhagic stroke are for BMIs above 25 kg/m
2 as described in text.
doi:10.1371/journal.pone.0065174.g003
Cardiometabolic Risk Effect Sizes
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[42]. For cholesterol, while Asian cohorts had subjects with TC
levels below 4.0 mmol/L and estimated associations to as low as
3.8 mmol/L for IHD [11,43], other epidemiological studies report
mean levels of 4.0 mmol/L or more [8]. There may also be an
increased risk of haemorrhagic stroke at low cholesterol levels
[11],[44,45]. Therefore we selected TMRED based on the low
levels observed in observational studies and did not use
randomized trials of statins because, as described earlier, statins
may exert protective effects through pathways other than lowering
cholesterol.
The observed rise in mortality at lower BMI levels may in some
cases be due to ‘reverse causality’, as weight loss may precede
death by a decade or more for many chronic diseases, particularly
respiratory diseases and cancer. This phenomenon is also reflected
in a more consistent dose-response relationship when analyses are
restricted to never-smokers or when the first 5–15 years of follow-
up or deaths from respiratory diseases are excluded. The lowest
risk of all-cause mortality in the PSC dose-response analysis was at
BMIs of 22–23 kg/m
2 [22], higher than the 20–21 kg/m
2
suggested by APCSC for IHD and diabetes [13]. All-cause as
well as CVD and cancer mortality risk was lowest at 20–22.4 kg/
m
2 in the National Cancer Institute Cohort Consortium when the
first 15 years of follow-up and ever-smokers were excluded (noting
that all but one cohort had used self-reported weight and height)
[14]. Finally, for FPG, the ERFC analysis indicated a lowest risk of
CHD at levels between 4.9 and 5.3 mmol/L [18].
To use this new evidence and to reflect the uncertainties in the
TMRED, we have selected the following ranges for TMRED
mean (SD): 110–115 (4–6) mmHg for SBP, 3.8–4.0 (0.5–0.65)
mmol/L for TC, 21–23 (1.1–1.8) kg/m
2 for BMI and 4.9–5.3
(0.4–0.6) mmol/L for FPG. These TMREDs reflect the evidence
summarized above and the empirically observed low ranges in
some populations while avoiding exposing a large proportion of
the population to increased risk of mortality (e.g. from haemor-
rhagic stroke for TC or from diseases affected by underweight for
BMI).
Discussion
Randomized trials and observational studies provide strong
evidence on etiologic effects of metabolic risk factors on CVD
incidence and mortality. Our results summarize the evidence on
the magnitude of these effects from large cohort pooling projects
from different regions of the world and provide consistent,
comparable age-specific estimates of effect sizes. We found that
for the four selected risk factors, proportional effects declined with
age, while being generally consistent for Western vs. Asian
populations; key exceptions were effects of BMI on diabetes and
HHD. These estimates are essential to estimate global, regional
and national disease burden that is attributable to these risk factors
and inform clinical decisions and public health policies.
Figure 4. Relative risks (RRs) for diseases associated with fasting plasma glucose (FPG). The figure shows RRs for 1 mmol/L higher usual
or baseline FPG. The figure shows RRs converted to comparable age group as described in Methods. See Table S1 for RRs in original age groups from
each study. The percentage of variation in the pooled estimates that is due to statistical heterogeneity was evaluated using the I
2 statistic for each
age group and outcome. All I
2 values for these outcomes and age groups were zero.
doi:10.1371/journal.pone.0065174.g004
Cardiometabolic Risk Effect Sizes
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factor exposure data must be measured or estimated for the
population of interest and is likely to vary geographically and over
time. On the other hand, effect sizes are often derived from
epidemiological studies conducted in a different population for two
reasons: First, well-designed epidemiological studies can provide
unbiased estimates for the causal effects of risk factors that reflect
the underlying biological relationships and tend to be generaliz-
able to other populations. Second, it would be prohibitively costly
to conduct high-quality epidemiological studies to estimate effect
sizes locally for each risk assessment analysis. With an increasing
number of high-quality epidemiological studies being published,
there is also a need to decide whether to use effect sizes from
individual studies, e.g. those conducted in populations more
similar to the risk assessment population, or to pool several studies.
The former approach would preserve the potentially real
differences in effect size across populations. On the other hand,
effect sizes from individual studies are affected by sampling
variability, motivating pooling of estimates across several studies
[46] similar to our approach in this analysis.
Our analysis has several strengths: we estimated age-specific
RRs accounting for the age pattern of RRs using consistent and
comparable methods; we included recent pooling studies in at least
two regions for most risk factor-disease pairs; we conducted re-
analysis of previous pooling studies to increase comparability in
relation to age groups and adjustment for regression dilution bias;
we quantified uncertainty incorporating both the sampling
variability of the RRs from each cohort pooling study and the
uncertainty due to interpolating or extrapolating RRs into
consistent age groups.
These results should also be interpreted with some limitations in
mind. The pooling studies used in our analysis only covered
cohorts from North America, Western Europe and the Asia-
Pacific. The recently reported prospective cohort studies collab-
oration in South Asia [15] could not be used because it has so far
not reported effect sizes for the specific diseases analyzed here.
The appropriate balance between new observational studies that
inform risk factor effect sizes vs. evaluating known risk factor
interventions in developing countries [47,48] may be debated.
While we attempted to use sources that had pooled distinct
cohorts, some cohorts were included in more than one pooling
project. Further, despite our efforts to pool effect sizes for disease
outcomes that had the same definitions and measurements, some
differences remained. Specifically, the effect of BMI on diabetes in
PSC was estimated using diabetes deaths as the outcome whereas
in APCSC the outcome was diabetes incidence.
We pooled evidence on the CVD effects of risk factors from
observational studies. Therefore, unmeasured and residual con-
founding cannot be ruled out. This is less of a concern for SBP and
TC where there is overwhelming evidence from randomized trials
of antihypertensives and cholesterol-lowering drugs that corrob-
orate the evidence from observational studies on causal effects and
their magnitude [8,31,32]. For BMI and FPG, confounding
remains a concern as evidence from randomized trials of disease
outcomes is either very limited for practical reasons (BMI) or
provides mixed results (FPG) [49–52]. The biological plausibility
of a causal role for BMI is supported by the effects observed in
trials of bariatric surgery on mediators such as SBP, TC and FPG
[53,54] and results of bariatric surgery on cardiovascular events in
severely obese patients [55]. Several meta-analyses of randomized
trials of intensive versus moderate glucose lowering in diabetic
patients have shown significant reduction in the risk of myocardial
infarction and other major cardiovascular events [56–58]. In
particular, a meta-analysis of the 4 largest randomized trials
concluded that more intensive glucose lowering causes a ‘‘modest
but significant cardiovascular benefit in the short to medium term’’
[57]. For these reasons, and considering the overwhelming
evidence from observational studies of the graded increase in risk
of CVD with higher blood glucose levels, we included IHD and
stroke as outcomes of high blood glucose. However, some recent
randomized trials have failed to show a significant beneficial effect
of intensive glucose lowering in diabetic patients on CVD
mortality, possibly because of relatively old age and frailty of
participants, long duration of diabetes at baseline and high
prevalence of existing atherosclerotic disease at trial entry as well
as lower incidence of CVD in trial populations due to concurrent
treatment with statins, aspirin and antihypertensives which
reduced the power of the trials to detect an effect [59]. Another
issue is that some trials have been of short duration, perhaps too
short to have observed an effect [60].
Recent analyses of national and regional trends in exposure to
CVD risk factors have shown considerable worldwide increases in
BMI [26] and blood glucose [24], concurrent with increases in
SBP and TC in some regions [23,25]. Such trends will result in
substantial CVD burden in developing countries and economies in
transition in the near future. Periodic and consistent monitoring of
trends and the effects of these risk factors on disease burden is
needed in prioritizing prevention programs. Our results provide
robust, comparable, quantitative estimates of the effects of major
metabolic risk factors on CVD and diabetes and are essential for
informing health policies, setting prevention priorities, and
estimating disease burden attributable to these risk factors.
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